Treatment of Advanced Bladder Cancer

  • Mark S. Soloway
Part of the Ettore Majorana International Science Series book series (EMISS, volume 8)

Abstract

As we analyze our “progress” in the management of patients with bladder cancer with particular emphasis on patients with invasive tumors (T2+), we are keenly aware of our limited ability to cure the disease at this stage. Since we seem to be altering the natural history of the disease for patients identified with superficial bladder cancer we must focus some of our effort on earlier diagnosis and initiation of therapy. A recent report by Kaye et al.,[1] indicated that a high percentage of patients with invasive bladder cancer were first seen by a physician when tumors had already infiltrated. Since this data has important implications I sought to see if our patient population at the University of Tennessee Center for the Health Sciences and associated hospitals was similar. The primary question we sought to ask was “When do patients with advanced bladder cancer first seek medical care? How many with invasive tumors were initially diagnosed with superficial tumors?”

Keywords

Toxicity Platinum Adenocarcinoma Neuropathy Sarcoma 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    K. W. Kaye and P. H. Lange, Mode of presentation of invasive bladder cancer: Reassessment of the problem, J.Urol., 128: 31 (1982).Google Scholar
  2. 2.
    W. F. Whitmore, Jr., Management of invasive bladder neoplasms, Sem.in Urology, 1: 34 (1983).Google Scholar
  3. 3.
    B. Van der Werf-Messing, Preoperative irradiation followed by cystectomy to treat carcinoma of the urinary bladder category T3 Nx, MO, Int.J.Rad.Oncol.Biol.Phys., 5: 395 (1979).CrossRefGoogle Scholar
  4. 4.
    M. J. Droller, The controversial role of radiation therapy as adjunctive treatment of bladder cancer, J.Urol., 129: 897 (1983).Google Scholar
  5. 5.
    H. M. Radwin, Radiotherapy in bladder cancer: A critical review, J.Urol., 124: 43 (1980).Google Scholar
  6. 6.
    J. P. Blandy, H. R. England, S. J. Evans, H. F. Hope-Stone, G. M. Mair, B. S. Mantell, R. T. Oliver, A. M. Pierce, and R. A. Resdon, T3 bladder cancer — the case for salvage cystectomy, Brit.J.Urol., 52: 506 (1980).CrossRefGoogle Scholar
  7. 7.
    H. D. Pearse, J. T. Pappas, and C. V. Hodges, Radical cystectomy of bladder cancer: 10 year survival, J.Urol., 109: 623 (1973).Google Scholar
  8. 8.
    Z. Wajsman, C. Merrin, R. Bore, and G. P. Murphy, Current results in treatment of bladder tumors with total cystectomy at Roswell Park Memorial Institute, J.Urol., 113: 806 (1975).Google Scholar
  9. 9.
    J. E. Montie, Technique of radical cystectomy, Sem.in Urol., 1: 42 (1983).Google Scholar
  10. 10.
    F. S. Freiha, Complications of cystectomy, J.Urol., 123: 168 (1980).Google Scholar
  11. 11.
    D. G. Skinner, E. D. Crawford, and J. J. Kaufman, Complications of radical cystectomy for carcinoma of the bladder, J.Urol., 123: 640 (1980).Google Scholar
  12. 12.
    D. E. Johnson and S. M. Lamy, Complications of a single stage radical cystectomy and ileal conduit diversion: Review of 214 cases, J.Urol., 117: 171 (1977).Google Scholar
  13. 13.
    J. J. Roberts and J. M. Pascoe, Cross-linking of complimentary strands of DNA in malignant cells by anti-tumor platinum compounds, Nature, 235: 282 (1972).ADSCrossRefGoogle Scholar
  14. 14.
    C. L. Litterest, Alterations in the toxicity of cis-diamminedi- choloplatium (II) and in tissue localization of platinum as a function of NaC concentration in the vehicle of administration, Toxicol Appl.Pharmacol., 61: 99–108 (1981).CrossRefGoogle Scholar
  15. 15.
    A. Yagoda, Chemotherapy for advanced urothelial cancer, Sem.in Urol., 1: 60 (1983).Google Scholar
  16. 16.
    M.S. Soloway, A. Einstein, J. Coombs, M. P. Corder, G. R. Prout Jr., and W. Bonney, A comparison of cis-platin and the combination of cis-platin and cyclophosphamide in advanced urothelial cancer — A National Bladder Cancer Collaborative Group A study, Cancer, (in press).Google Scholar
  17. 17.
    A. Yagoda, R. C. Watson, N. Kemeny, W. Barzell, H. Grabstald, and W. F. Whitmore, Diamminedichloride platinum II and cyclophosphamide in the treatment of advanced urothelial cancer, Cancer, 42: 2121–2130 (1978).CrossRefGoogle Scholar
  18. 18.
    A. Yagoda, Phase II trials with cis-diamminedichloride platinum II in the treatment of urothelial tract tumors, Cancer Treat Rep., 63: 1565–1572 (1979).Google Scholar
  19. 19.
    A. Yagoda, Chemotherapy of metastatic bladder cancer, Cancer, 45: 1879–1888 (1980).Google Scholar
  20. 20.
    P. H. Smith, Chemotherapy of bladder cancer. A review, Cancer Treat.Rep., 65: 165–173 (1981).Google Scholar
  21. 21.
    A. Yagoda, G. Bosl, and H. Scher, Advances in chemotherapy of bladder cancer, in: “Recent Advances in Urologic Cancer”, N. Javadpour ed., Williams and Wilkin Co., Baltimore, pp. 211–254 (1982).Google Scholar
  22. 22.
    J. D. Khandekar, P. J. Elson, and W. D. Dewys, Comparative activity and toxicity of cis-diamminedichloroplatinum vs. cyclophosphamide, adriamycin and DDP (CAD) in disseminated transitional cell carcinoma of the urinary tract, Proc.Am. Ass.Cancer Res., 22: 461 (1981).Google Scholar
  23. 23.
    M. L. Samuels, C. Logothetis, A. Trindade, and D. E. Johnson, Cytoxan, adriamycin and cis-platinum (CISCA) in metastatic bladder cancer. (Abstract #C415) Proc.Am.Assoc.Cancer Res., 21: 137 (1980).Google Scholar
  24. 24.
    M. Troner and G. Hemstreet, Cyclophosphamide, adriamycin and cis-platinum (CAP) chemotherapy of metastatic transitional cell carcinoma of the bladder, (Abstract #642) Proc.Am.Assoc. Cancer Res., 19: 161 (1978).Google Scholar
  25. 25.
    A. G. Turner, Methotrexate, in: “Bladder Cancer — Principles of Combination Therapy”, R. T. D. Oliver, W. T. Hendry, and H. J. G. Bloom, eds., Kent, Butterworth, pp.219–229 (1981).Google Scholar
  26. 26.
    R. T. D. Oliver, Methotrexate as salvage or adjunctive therapy for primary invasive carcinoma of the bladder, Cancer Treat Rep., 65: 179–181 (1981).Google Scholar
  27. R. B. Natale, A. Yagoda, R. C. Watson, and W. F. Whitmore, Methotrexate: An active drug in bladder cancer, Cancer, 47: 1246–1250 (1981).CrossRefGoogle Scholar
  28. 28.
    O. R. Gagliano, Adriamycin vs. adriamycin plus cisplatinum in transitional cell bladder carcinoma: A SWOG study (Abstract #C-110), Proc.Am.Assoc.Cancer Res., 21: 347 (1980).Google Scholar
  29. 29.
    EORTC: The treatment of advanced carcinoma of the bladder with a combination of adriamycin and 5-fluorouracil, Eur.Urol., 3: 276–278 (1977).Google Scholar
  30. 30.
    M. S. Blumenreich, A. Yagoda, R. B. Natale, and W. F. Whitmore, Phase II trial of vinblastine sulfate for metastatic urothelial tract tumors, Cancer, 50: 435–438 (1982).CrossRefGoogle Scholar
  31. 31.
    P. H. Smith, Presented at the Second International Conference — A treatment of urinary tract tumors with adriamycin, San Francisco, CA, September 4, (1982).Google Scholar
  32. 32.
    D. G. Skinner, G. Leskovsky, and J. R. Daniels, Adjuvant chemo therapy following cystectomy for deeply invasive bladder cancer: Current status, Proc.of the AUA, p. 130 (1983).Google Scholar
  33. 33.
    K. H. Luk, G. Y. Ross, T. L. Phillips, and L. S. Goldstein, The interaction of radiation and cis-diamminedichloroplatinum (II) in intestinal crypt cells, Int.J.Rad.Oncol.Biol.Phys., 5: 1471 (1979).CrossRefGoogle Scholar
  34. 34.
    E. B. Douple, W. L. Eaton, Jr., and M. C. Tulloh, Skin radio- sensitization studies using combined cis-dichlorodiammed- platinum (II) and radiation, Int.J.Rad.Oncol.Biol.Phys., 5: 1382 (1979).Google Scholar
  35. 35.
    D. R. Burholt, L. L. Schenken, C. J. Kovacs, and R. F. Hageman, Response of the murine gastrointestinal epithelium to cis- dichlorodiammineplatinum (II) radiation combinations, Int.J. Rad.Oncol.Biol.Phys., 5: 1377 (1979).CrossRefGoogle Scholar
  36. 36.
    F. M. Maggia and E. Glatstein, Summary of investigations on platinum compounds and radiation interactions, Int.J.Rad. Oncol.Biol.Phys., 5: 1407 (1979).CrossRefGoogle Scholar
  37. 37.
    M. S. Soloway, C. R. Morris, and B. Sudderth, Radiation therapy in cis- diamminedichloroplatinum in transplantable and primary murine bladder cancer, Int.J.Rad.Oncol.Biol.Phys., 5: 1355 (1979).CrossRefGoogle Scholar
  38. 38.
    R. J. Babaian, D. E. Johnson, L. Llamas, and A. G. Ayala, Metasteses from transitional cell carcinoma of urinary bladder, Urology, 16: 142 (1980).CrossRefGoogle Scholar
  39. 39.
    G. Jakse, H. Frommhold, and H. Marberger, Combined cis-platinum and radiation therapy in patients with stage pT3 and pT4 bladder cancer: A pilot study, J.Urol., 129: 1502 (1983).Google Scholar
  40. 40.
    S. Wallace, V, P. Chuang, M. Sanuels, and D. Johnson, Trans- catheter intra-arterial infusion of chemotherapy in advanced bladder cancer, Cancer419: 640 (1982)CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1985

Authors and Affiliations

  • Mark S. Soloway
    • 1
  1. 1.Department of UrologyBaptistMemorial HospitalMemphisUSA

Personalised recommendations